Pictilisib (GDC-0941)

For research use only. Not for use in humans.

目录号：S1065 别名： RG7321

Pictilisib (GDC-0941) Chemical Structure

Molecular Weight(MW): 513.64

Pictilisib (GDC-0941) 是一种有效的PI3Kα/δ抑制剂，在无细胞试验中IC50为 3 nM，对p110β (11倍)和p110γ (25倍)具有适度的选择性。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1972.48	现货
5mg	RMB 986.88	现货
10mg	RMB 1390.74	现货
50mg	RMB 3026.17	现货
200mg	RMB 7926.11	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Pictilisib (GDC-0941)发表文献294篇：

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Med, 2017, 23(11):1342-1351

PubMed: 29035366 ( click the link to review the publication )

J Clin Oncol, 2016, 34(8):794-802

PubMed: 26215952 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Nature, 2014, 508(7494):118-22

PubMed: 24670642 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):94-109

PubMed: 24265153 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Eur J Pharmacol, 2020, 873:172981

PubMed: 32014486 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

J Clin Invest, 2019, 129(12):5584-5599

PubMed: 31527310 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1473

PubMed: 30931927 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Cancer Res, 2019, 79(6):1138-1150

PubMed: 30679179 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(9):2835-2847

PubMed: 30670492 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2892-2908

PubMed: 31048499 ( click the link to review the publication )
Cell Rep, 2019, 27(1):294-306

PubMed: 30943409 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2317-2330

PubMed: 31461649 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.216218

PubMed: 31471373 ( click the link to review the publication )

Int J Cancer, 2019, 145(3):817-829

PubMed: 30671946 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

MBio, 2019, 10(1)

PubMed: 30755508 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

J Invest Dermatol, 2019, 139(9):2004-2015

PubMed: 31059696 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):41

PubMed: 30691487 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):236

PubMed: 31164152 ( click the link to review the publication )

Cells, 2019, 8(2)

PubMed: 30795621 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-1332

PubMed: 31043489 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2395-2409

PubMed: 31548239 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:839-855

PubMed: 30697076 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):431-442

PubMed: 30483742 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

Int J Mol Med, 2019, 44(5):1789-1800

PubMed: 31545402 ( click the link to review the publication )

Pestic Biochem Physiol, 2019, 154:67-77

PubMed: 30765058 ( click the link to review the publication )

Contrast Media Mol Imaging, 2019, 2019:1760184

PubMed: 31787861 ( click the link to review the publication )

Life Sci Alliance, 2019, 2(6)

PubMed: 31704709 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )
Blood, 2018, 10.1182/blood-2018-08-872465

PubMed: 30322870 ( click the link to review the publication )

Mol Cell, 2018, 71(6):1092-1104

PubMed: 30174291 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4945

PubMed: 30470748 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

Genes Dev, 2018, 32(17-18):1201-1214

PubMed: 30143526 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

NPJ Genom Med, 2018, 3:15

PubMed: 29951225 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

J Cell Biol, 2018, 217(5):1701-1717

PubMed: 29545370 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Cell Rep, 2018, 22(4):860-868

PubMed: 29420173 ( click the link to review the publication )

Oncogene, 2018, 37(10):1369-1385

PubMed: 29311642 ( click the link to review the publication )

Cancer Lett, 2018, 439:56-65

PubMed: 30243708 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30545064 ( click the link to review the publication )

Cell Death Dis, 2018, 9(8):809

PubMed: 30042442 ( click the link to review the publication )

Bioinformatics, 2018, 34(17):i997-i1004

PubMed: 30423075 ( click the link to review the publication )

Bioinformatics, 2018, 34(23):4079-4086

PubMed: 29931053 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):71

PubMed: 30237393 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

J Am Heart Assoc, 2018, 7(6)

PubMed: 29514810 ( click the link to review the publication )
Am J Physiol Lung Cell Mol Physiol, 2018, 315(6):L965-L976

PubMed: 30211651 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2018, 58(2):181-193

PubMed: 28915060 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

Int J Oncol, 2018, 53(5):1881-1896

PubMed: 30132519 ( click the link to review the publication )

Proteomics, 2018, 18(23):e1800244

PubMed: 30267477 ( click the link to review the publication )

Invest New Drugs, 2018, 36(5):763-772

PubMed: 29504069 ( click the link to review the publication )

Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )

Prostate, 2018, 78(13):1013-1023

PubMed: 30133757 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):715-725

PubMed: 29901201 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0193849

PubMed: 29799846 ( click the link to review the publication )

PLoS One, 2018, 13(8):e0200725

PubMed: 30067771 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

JCI Insight, 2018, 3(4)

PubMed: 29467326 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):611-618

PubMed: 28494242 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2249

PubMed: 29269732 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(18):5561-5572

PubMed: 28606920 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4135-4145

PubMed: 28615225 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1892-1904

PubMed: 28108509 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )
Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Oncogene, 2017, 36(41):5681-5694

PubMed: 28604746 ( click the link to review the publication )

Oncogene, 2017, 36(36):5110-5121

PubMed: 28481878 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0415

PubMed: 28119489 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1054-1067

PubMed: 28336808 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2130-2143

PubMed: 28751539 ( click the link to review the publication )

Oncogenesis, 2017, 6(11):398

PubMed: 29184057 ( click the link to review the publication )

Cell Discov, 2017, 3:16054

PubMed: 28224045 ( click the link to review the publication )

Mol Pharm, 2017, 14(7):2368-2377

PubMed: 28597653 ( click the link to review the publication )

J Immunol, 2017, 198(2):657-668

PubMed: 27940659 ( click the link to review the publication )

Sci Rep, 2017, 7(1):5519

PubMed: 28717217 ( click the link to review the publication )

Sci Rep, 2017, 7(1):3964

PubMed: 28638122 ( click the link to review the publication )

Mol Pharmacol, 2017, 91(1):65-73

PubMed: 27821547 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(10):816-826

PubMed: 29099264 ( click the link to review the publication )

Biol Reprod, 2017, 97(5):671-687

PubMed: 29036279 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181243

PubMed: 28704514 ( click the link to review the publication )

Curr Cancer Drug Targets, 2017, 17(8):722-734

PubMed: 28359246 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Oncotarget, 2017, 8(3):5349-5360

PubMed: 28029662 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7878-7890

PubMed: 28002802 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )
Oncotarget, 2017, 8(4):6608-6622

PubMed: 28036259 ( click the link to review the publication )

Oncotarget, 2017, 8(2):3259-3273

PubMed: 27965462 ( click the link to review the publication )

Oncotarget, 2017, 8(26):42343-42358

PubMed: 28418845 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52877-52888

PubMed: 28881779 ( click the link to review the publication )

Oncotarget, 2017, 8(8):12558-12575

PubMed: 28147342 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63901-63910

PubMed: 28969039 ( click the link to review the publication )

Physiol Rep, 2017, 5(18)

PubMed: 28947594 ( click the link to review the publication )

Oncotarget, 2017, 8(47):83052-83062

PubMed: 29137323 ( click the link to review the publication )

Oncotarget, 2017, 9(10):8870-8886

PubMed: 29507660 ( click the link to review the publication )

Nat Commun, 2016, 7:13567

PubMed: 27876799 ( click the link to review the publication )

Nat Commun, 2016, 7:13650

PubMed: 27897192 ( click the link to review the publication )

Nat Commun, 2016, 7:13650

PubMed: 27897192 ( click the link to review the publication )

Nat Commun, 2016, 7:13567

PubMed: 27876799 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1345-1356

PubMed: 27117832 ( click the link to review the publication )

Leukemia, 2016, 30(9):1832-43

PubMed: 27174491 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cell Rep, 2016, 15(12):2692-704

PubMed: 27292631 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27700986 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Oncogene, 2016, 35(27):3587-97

PubMed: 26549034 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(3):317-28

PubMed: 26850518 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(3):317-28

PubMed: 26850518 ( click the link to review the publication )
Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

Development, 2016, 143(23):4368-4380

PubMed: 27660325 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1545-56

PubMed: 27196766 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1248-60

PubMed: 27197306 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(1):94-105

PubMed: 26637365 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3507-3519

PubMed: 27992857 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016, 6:37213

PubMed: 27849011 ( click the link to review the publication )

PLoS Comput Biol, 2016, 12(4):e1004827

PubMed: 27035903 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19575-88

PubMed: 26988909 ( click the link to review the publication )

Oncotarget, 2016, 7(28):44448-44461

PubMed: 27286446 ( click the link to review the publication )

Oncotarget, 2016, 7(28):43124-43149

PubMed: 27281609 ( click the link to review the publication )

Oncotarget, 2016, 7(36):57525-57544

PubMed: 27438153 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9188-221

PubMed: 26802026 ( click the link to review the publication )

Oncotarget, 2016, 7(50):82424-82439

PubMed: 27489350 ( click the link to review the publication )

Nat Commun, 2015, 6:7212

PubMed: 25998442 ( click the link to review the publication )

Nat Commun, 2015, 6:7935

PubMed: 26228240 ( click the link to review the publication )

Nat Commun, 2015, 6:8501

PubMed: 26442967 ( click the link to review the publication )

J Exp Med, 2015, 212(6):883-92

PubMed: 25987726 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2015, 112(28):8638-43

PubMed: 26124089 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

Elife, 2015, 4:e10510

PubMed: 26523394 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25686219 ( click the link to review the publication )

Int J Cancer, 2015, 10.1002/ijc.29579

PubMed: 25912635 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(12):3115-3124

PubMed: 26302068 ( click the link to review the publication )

Sci Signal, 2015, 8(401):ra111

PubMed: 26535009 ( click the link to review the publication )

Sci Signal, 2015, 8(396):ra96

PubMed: 26420907 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2015, 28(5):572-89

PubMed: 26112748 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1591

PubMed: 25590801 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:26

PubMed: 25975820 ( click the link to review the publication )

Neoplasia, 2015, 17(8):625-33

PubMed: 26408255 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(4):926-38

PubMed: 25292196 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

J Biol Chem, 2015, 290(35):21705-12

PubMed: 26152725 ( click the link to review the publication )

J Biol Chem, 2015, 290(40):24367-80

PubMed: 26294766 ( click the link to review the publication )

Proteomics, 2015, 15(2-3):327-39

PubMed: 25339196 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(3):402-11

PubMed: 25692408 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: 25327687 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(4):648-55

PubMed: 25590338 ( click the link to review the publication )
PLoS One, 2015, 10(11):e0143357

PubMed: 26580203 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0122689

PubMed: 25837824 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0133610

PubMed: 26402468 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0131400

PubMed: 26148118 ( click the link to review the publication )

Oncotarget, 2015, 6(11):9189-205

PubMed: 25826077 ( click the link to review the publication )

Oncotarget, 2015, 6(39):41976-87

PubMed: 26506516 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(11):8722-35

PubMed: 25749378 ( click the link to review the publication )

Crit Rev Oncol Hematol, 2015, 96(3):507-17

PubMed: 26253360 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43540-56

PubMed: 26498353 ( click the link to review the publication )

Oncotarget, 2015, 6(31):32089-103

PubMed: 26392332 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(18):16488-506

PubMed: 26029997 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33091-105

PubMed: 26384305 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2014, 111(47):16826-9

PubMed: 25385636 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cancer Res, 2014, 74(17):4597-4611

PubMed: 25183785 ( click the link to review the publication )

Oncogene, 2014, 33(26):3422-31

PubMed: 23912457 ( click the link to review the publication )

Oncogene, 2014, 33(8):966-76

PubMed: 23474757 ( click the link to review the publication )

Oncogene, 2014, 33(35):4418-23

PubMed: 24469055 ( click the link to review the publication )
Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

Oncogene, 2014, 33(23):3043-53

PubMed: 23893244 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Pain, 2014, 155(6):1150-60

PubMed: 24631588 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Neoplasia, 2014, 16(2):147-57

PubMed: 24709422 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Am J Cancer Res, 2014, 4(6):824-37

PubMed: 25520871 ( click the link to review the publication )

J Immunol, 2014, 193(6):3036-44

PubMed: 25092892 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112148

PubMed: 25386922 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84746

PubMed: 24404189 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )

Mol Med Rep, 2014, 9(1):83-90

PubMed: 24213221 ( click the link to review the publication )

Anticancer Drugs, 2014, 25(2):183-8

PubMed: 24100276 ( click the link to review the publication )

Oncotarget, 2014, 5(16):7081-92

PubMed: 25216524 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7936-44

PubMed: 25277205 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6512-25

PubMed: 25156567 ( click the link to review the publication )
Harvard University, 2014,

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )

Sci Transl Med, 2013, 5(196):196ra98

PubMed: 23903755 ( click the link to review the publication )

Sci Transl Med, 2013, 5(196):196ra98

PubMed: 23903755 ( click the link to review the publication )

Blood, 2013, 121(12):2274-84

PubMed: 23341541 ( click the link to review the publication )

J Clin Invest, 2013, 123(6):2551-63

PubMed: 23635776 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Leukemia, 2013, 27(11):2118-28

PubMed: 23535559 ( click the link to review the publication )

Cancer Res, 2013, 73(3):1190-200

PubMed: 23204226 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Haematologica, 2013, 98(1):57-64

PubMed: 22801959 ( click the link to review the publication )

Oncogene, 2013, 33(9):1190-7

PubMed: 23435426 ( click the link to review the publication )

Sci Signal, 2013, 6(288):ra68

PubMed: 23943608 ( click the link to review the publication )

Sci Signal, 2013, 6(268):ra20

PubMed: 23532334 ( click the link to review the publication )

PLoS Genet, 2013, 9(2):e1003253

PubMed: 23459592 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(12):2950-61

PubMed: 24107445 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 5):1099-108

PubMed: 23345407 ( click the link to review the publication )

Cancer Sci, 2013, 104(8):1027-32

PubMed: 23710822 ( click the link to review the publication )

J Biol Chem, 2013, 288(21):14698-708

PubMed: 23585567 ( click the link to review the publication )

Front Genet, 2013, 4:34

PubMed: 23543623 ( click the link to review the publication )

Front Genet, 2013, 4:34

PubMed: 23543623 ( click the link to review the publication )

Cell Cycle, 2013, 12(12):1892-900

PubMed: 23676220 ( click the link to review the publication )
Cancer Med, 2013, 2(1):76-85

PubMed: 24133630 ( click the link to review the publication )

FEBS Lett, 2013, 587(1):5-16

PubMed: 23178716 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77243

PubMed: 24130864 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66306

PubMed: 23824914 ( click the link to review the publication )

Mol Biosyst, 2013, 9(2):234-45

PubMed: 23168618 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 435(4):557-61

PubMed: 23665330 ( click the link to review the publication )

Leuk Res, 2013, 38(1):109-15

PubMed: 23981382 ( click the link to review the publication )

J Surg Res, 2013, 184(2):898-906

PubMed: 23602735 ( click the link to review the publication )

Oncotarget, 2013, 4(8):1185-98

PubMed: 23852390 ( click the link to review the publication )

Oncotarget, 2013, 4(8):1185-98

PubMed: 23852390 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2502-14

PubMed: 22351686 ( click the link to review the publication )

Clin Cancer Res, 2012, 19(3):657-67

PubMed: 23251002 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(31):E2127-33

PubMed: 22773810 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e400

PubMed: 23059819 ( click the link to review the publication )

J Cell Sci, 2012, 125(Pt 5):1259-73

PubMed: 22399812 ( click the link to review the publication )

Cancer Sci, 2012, 103(9):1665-71

PubMed: 22703543 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(12):2210-6

PubMed: 22974639 ( click the link to review the publication )

J Leukoc Biol, 2012, 92(1):219-31

PubMed: 22544939 ( click the link to review the publication )

Mol Cell Biol, 2012, 32(22):4674-83

PubMed: 22988297 ( click the link to review the publication )

PLoS One, 2012, 7(8):e44146

PubMed: 22952903 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Oncotarget, 2012, 3(8):811-23

PubMed: 22885370 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(24):7595-604

PubMed: 22038996 ( click the link to review the publication )
Clin Cancer Res, 2011, 17(8):2260-9

PubMed: 21220474 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(37):E699-708

PubMed: 21876152 ( click the link to review the publication )

Cancer Res, 2011, 71(7):2750-60

PubMed: 21317224 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(2):495-503

PubMed: 21048785 ( click the link to review the publication )

Sci Signal, 2011, 4(192):ra62

PubMed: 21954288 ( click the link to review the publication )

Thyroid, 2010, 20(7):689-95

PubMed: 20578898 ( click the link to review the publication )

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述

Pictilisib (GDC-0941) 是一种有效的PI3Kα/δ抑制剂，在无细胞试验中IC50为 3 nM，对p110β (11倍)和p110γ (25倍)具有适度的选择性。Phase 2。

靶点

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR ^[1] (Cell-free assay)
3 nM	3 nM	33 nM	75 nM	0.58 μM(Ki app)

体外研究

GDC-0941也等效作用于PI3Kα和 PI3Kδ和PI3Kα突变型E545-K和H1047-R,也选择性作用于PI3Kβ(10倍)和 PI3Kγ(25倍), 选择性更高地作用于PI3K II, III, 和IV类成员，包括, C2β, Vps34, DNA-PK和mTOR。GDC-0941 作用于U87MG, PC3, 和 MDA-MB-361 细胞，有效抑制Akt磷酸化，IC50分别为46 nM, 37 nM,和 28 nM。GDC-0941抑制U87MG, A2780, PC3, 和MDA-MB-361细胞增殖，IC50分别为 0.95 μM, 0.14 μM, 0.28 μM, 和0.72 μM。^[1]GDC-0941处理，有效抑制对Trastuzumab敏感和不敏感的HER2扩增细胞增殖，IC50为149-944 nM,与 Trastuzumab敏感性无关。GDC-0941抑制含PIK3CA突变的HER2扩增的细胞增殖，IC50<500 nM, 且有效抑制抗trastuzumab 的HER2 扩增乳腺癌细胞增殖和活力。^[2]GDC-0941 显著抑制HCT116, DLD1和 HT29细胞生长，GI50分别为1081 nM, 1070 nM 和157 nM。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Sf9	MnK0T4lv[XOnIFHzd4F6		MYKxJIg>	NUnxO\|hzTE2VTx?=	MWrJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGSnbIThJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiY3;lfJBz\XO\|aX7nJJA5PWGucHjhJJdqfGhiSVO1NEBw\iByLkCwN{DPxE1?	MofyNVg4PTR4NUS=
Sf9	NHvoSFRMcW6jc3WgRZN{[Xl?		MmTtNUBp	MYHEUXNQ	M3L4S2lvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUFmzT{BxOTFyYnX0ZUBJOTB2Nz3SJI12fGGwdDDlfJBz\XO\|ZXSgbY4hW2Z7IHPlcIx{KGOxZYjwdoV{e2mwZzDwPFVidHCqYTD3bZRpKEmFNUCgc4YhOC5yMEOg{txO	MkDYNVg4PTR4NUS=
Sf9	NYfH[G9tU2mwYYPlJGF{e2G7		MWWxJIg>	MUnEUXNQ	MXXJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGKndHGgSVU1PS2NIH31eIFvfCCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJINw\XiycnXzd4lv\yCyOEXhcJBp[SC5aYToJGlEPTBib3[gNE4xODNizszN	NGT4T2YyQDd3NE[1OC=>
Sf9	NHzYbIlMcW6jc3WgRZN{[Xl?		NFHX[G8yKGh?	NX30eHlFTE2VTx?=	MULJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGKndHGg[ZhxemW\|c3XkJIlvKFOoOTDj[YxteyClb3X4dJJme3OrbnegdFg2[WyyaHGge4l1cCCLQ{WwJI9nKDBwMEOzJO69VQ>?	NHq4RZUyQDd3NE[1OC=>
Sf9	NHzIXHlMcW6jc3WgRZN{[Xl?		M3zHe\|EhcA>?	MmHmSG1UVw>?	MX\Jcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGGucHjhJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiY3;lfJBz\XO\|aX7nJJA5PWGucHjh	M3rD[\|E5PzV2NkW0
MDA-MB-361	MVHGeY5kfGmxbjDBd5NigQ>?		MoKyNkBp	M2m3U2ROW09?	NHLiPItKdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIF3ERU1OSi1\|NkGgZ4VtdHNid3n0bEBRUUt\|Q1GgSVU1PS2NIH31eIF1cW:wIIfpeIghUUN3MDDv[kAxNjB{ODFOwG0>	MXWxPFc2PDZ3NB?=
PC3	MVrGeY5kfGmxbjDBd5NigQ>?		MUeyJIg>	M2rUbmROW09?	MWTJcohq[mm2aX;uJI9nKEGtdDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4udnWubDDoeY1idiCSQ{OgZ4VtdHNid3n0bEBKSzVyIH;mJFAvODN5IN88US=>	NXXre49iOTh5NUS2OVQ>
U87MG	M1T0UWZ2dmO2aX;uJGF{e2G7		MVSyJIg>	NVjGVoxxTE2VTx?=	MWrJcohq[mm2aX;uJI9nKEGtdDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4udnWubDDoeY1idiCXOEfNS{Bk\WyuczD3bZRpKEmFNUCgc4YhOC5yNE[g{txO	MYSxPFc2PDZ3NB?=
MDA-MB-361	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{HRR\|k3KGh?	MWfEUXNQ	MoHYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuOzZzIHPlcIx{KHerdHigVGlMO0ODIFW1OFUuUyCvdYTheIlwdiC5aYToJGlEPTBib3[gNE44OiEQvF2=	NVnyb3ZCOTh5NUS2OVQ>
A2780	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlzmPVYhcA>?	NHXCVm9FVVOR	NXTXdZFnSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIGDJT\|NESSCjbnSgVHRGViCvdYTheIlwdiC5aYToJGlEPTBib3[gNE4yPCEQvF2=	M33VbFE5PzV2NkW0
PC3	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH;vfXU6PiCq	MlfBSG1UVw>?	Moj5TWM2OD1yLkK4JO69VQ>?	M1\CelE5PzV2NkW0
U87MG	NELJOFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVjBTYI{QTZiaB?=	NGTse2pFVVOR	NWCxe2dUUUN3ME2wMlk2KM7:TR?=	NGjxT4UyQDd3NE[1OC=>
Sf9	MVHLbY5ie2ViQYPzZZk>		NI\iW\|k{OCCvaX6=	MnOzSG1UVw>?	NFrZU4dKdmirYnn0bY9vKG:oIHj1cYFvKFCLM1vnZY1u[SCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgZY1wfW62IH;mJGFVWCClb37zeY1m\CC5aYToJGlEPTBib3[gNE4xPDJizszN	NYi1Z4E2OjJ3NEizOFI>
RAW 264.7	MlywT4lv[XOnIFHzd4F6		M1fKU\|kxKG2rbh?=	Mo\KSG1UVw>?	MVLJcohq[mm2aX;uJI9nKGi3bXHuJHBKO0upYX3tZUBmgHC{ZYPz[YQh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBCU1RicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlI6QCEQvF2=	MUSyNlU1QDN2Mh?=
Sf9	NGfNRZVMcW6jc3WgRZN{[Xl?		NIPmNVcyKGh?		MnjYTY5pcWKrdHnvckBw\iCJU2St[pV{\WRiaIXtZY4hemWlb33ibY5idnRiUFmzT4JmfGFiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOIOTDj[YxteyC5aYToJGlEPTBib3[gNE4xOTdizszN	MWiyN\|U1ODZ2NR?=
Sf9	Mn[1T4lv[XOnIFHzd4F6		NFH1VosyKGh?		MmTnTY5pcWKrdHnvckBw\iCJU2St[pV{\WRiaIXtZY4hemWlb33ibY5idnRiUFmzT4RmdHSjIHX4dJJme3OnZB?=	NUW5ZlRoOjN3NEC2OFU>
Sf9	MVfLbY5ie2ViQYPzZZk>		NXvxU4lqOSCq		NXLHPY5wUW6qaXLpeIlwdiCxZjDHV3Qu\nW\|ZXSgbJVu[W5icnXjc41jcW6jboSgVGk{U2ejbX3hJIV5eHKnc4Pl[C=>	MmDBNlM2PDB4NEW=
Sf9	NHTKd45McW6jc3WgRZN{[Xl?		MlnRNUBp		NYPTenNvUW6qaXLpeIlwdiCxZjDHV3Qu\nW\|ZXSgbJVu[W5icnXjc41jcW6jboSgVGk{U2GucHjhJIV5eHKnc4Pl[C=>	MYOyN\|U1ODZ2NR?=
SKOV3	M3XGZmtqdmG\|ZTDBd5NigQ>?	M1;4eFEh\|ryP	MX6xJIg>	NVPoTFByTE2VTx?=	NVjB[FR6UW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbh?=	NYHlPYNPOjN\|NkCzOFg>
MCF7	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX:xJO69VQ>?	MkXBPVYhcA>?	NHraOZlFVVOR	M{nYSWdKPTB;MD6wO\|AzKM7:TR?=	M37M[VI{OzZyM{S4
SKOV3	NIXkXYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\mRVEh\|ryP	NXm2epFIQTZiaB?=	MoPuSG1UVw>?	MlvVS2k2OD1yLkG0O\|Yh\|ryP	M3XxcFI{OzZyM{S4
PC3	M3ntfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmTMO\|IhcA>?	NFPhNnNFVVOR	Ml65TWM2OD1yLkK4JO69VQ>?	MlKzNlE6QDF5MUS=
MCF7.1	M2XnUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFfPT4E4OiCq	NXjZbItNTE2VTx?=	NYPH[3UzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4NjFiY3XscJMh\XiycnXzd4lv\yCKRWKyJIdmdmVid3n0bEBKSzVyIH;mJFAvOjhizszN	NX3sVINLOjF7OEG3NVQ>
MCF7-neo/Her2	M376UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3zE[lczKGh?	M1Lwb2ROW09?	NXfjSlhHUUN3ME2wMlI6KM7:TR?=	MUSyN\|Y3OjlyMx?=
MCF7-neo/Her2	MkD0T4lv[XOnIFHzd4F6				NVjT[HlFUW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKG:oIFHLWEBxcG:\|cHjvdplt[XSrb36gZZQhWzR5MzD3bZRpKEmFNUCgc4YhOC5yMEeg{txO	NVnrZo57OjN4NkK5NFM>
PC3	MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYXJ[ItTPzJiaB?=	NIHmZ2ZFVVOR	NXvZbYMzTUN3ME2wMlM1KM7:TR?=	M1P3[\|IyQTh3NkO5
MCF7.1	M2\nWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUm3NkBp	MkHUSG1UVw>?	MkHMRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3MlEh[2WubIOg[ZhxemW\|c3nu[{BRUTONYXzwbIEhdXW2YX70JJdqfGhiRVO1NEBw\iByLkO5JO69VQ>?	M1zDclIyQTh3NkO5
PC3	M4nndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NInT[ZY4OiCq	NHmzR4JFVVOR	MmPJRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCSQ{OgZ4VtdHNiZHXmbYNq\W62IHnuJHBVTU5id3n0bEBKSzVyIH;mJFAvOzlizszN	NEOyNW4zODB3ME[2PS=>
MCF7.1	NWS2NotST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGW1O444OiCq	MoK5SG1UVw>?	M17oe2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{4yKGOnbHzzJIV5eHKnc4PpcochWEl\|S3HsdIhiKG23dHHueEB4cXSqIFnDOVAhd2ZiMD6zOEDPxE1?	MojFNlAxPTB4Nkm=
MCF7.1	NHT0VXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH3VeIg4OiCq		MVLFR\|UxRTBwN{Kg{txO	NV7HbpVTOjB\|NE[2OVY>
NCI-H1975	NWDMVIF7S3m2b4TvfIlkKEG\|c3H5		NVLiWpF4PzJiaB?=		NWjueJQ6UUN3ME2wMlI4KM7:TR?=	M1PXZlI{ODV7NUS1
H460	NXvzTIxvS3m2b4TvfIlkKEG\|c3H5		M17sR\|czKGh?		NEW2[41KSzVyPUCuPFch\|ryP	NXzhXFd{OjNyNUm1OFU>
HT-29	M{PU[WN6fG:2b4jpZ{BCe3OjeR?=		NF3YXIc4OiCq		MX7JR\|UxRTBwNk[g{txO	MX:yN\|A2QTV2NR?=
HepG2	NH[yRWhEgXSxdH;4bYMhSXO\|YYm=		MVq3NkBp		NFGzblJKSzVyPUGg{txO	M{PFWVI{ODV7NUS1
SGC7901	MVXDfZRwfG:6aXOgRZN{[Xl?		NGflPZk4OiCq		Mke2TWM2OD1zLkig{txO	NVOyeZhQOjNyNUm1OFU>
NCI-H226	MmT3R5l1d3SxeHnjJGF{e2G7		M{O2SFczKGh?		MnPSTWM2OD1{Lkmg{txO	NHTPe44zOzB3OUW0OS=>
A549	MV;DfZRwfG:6aXOgRZN{[Xl?		Ml3hO\|IhcA>?		MX;JR\|UxRTZwOTFOwG0>	MX:yN\|A2QTV2NR?=
U87MG	MYrDfZRwfG:6aXOgRZN{[Xl?		NELMSJU4OiCq		NHKyPWVKSzVyPUeuO\|ch\|ryP	NHvDO40zOzB3OUW0OS=>
HBC4	Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPsc4dIUTVyPT22MlA{KE1?	MVWyNlM{PjJ2Nh?=
BSY1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELPOIttd2eJSUWwQU03NjlyIF2=	MmXvNlI{OzZ{NE[=
HBC5	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVj2NlRCdG:pR1m1NF0uPi54MDDN	NXPPVHdvOjJ\|M{[yOFY>
MCF7	M{mzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXX3Rph3dG:pR1m1NF0uPy5\|MzDN	M1;jclIzOzN4MkS2
MDA-MB-231	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmT6cI9oT0l3ME2tOU41PiCP	Mn[xNlI{OzZ{NE[=
U251	MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnsc4dIUTVyPT21MlUxKE1?	MXmyNlM{PjJ2Nh?=
SF268	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLlfnJHdG:pR1m1NF0uPS5\|OTDN	NEDQT44zOjN\|NkK0Oi=>
SF295	MoriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTaTHFYdG:pR1m1NF0uPi5\|NzDN	MVeyNlM{PjJ2Nh?=
SF539	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFX0XJptd2eJSUWwQU03NjVyIF2=	MlnNNlI{OzZ{NE[=
SNB75	NYHLTYg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\sc4dIUTVyPT23MlExKE1?	NY\RRmtbOjJ\|M{[yOFY>
SNB78	Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfxcI9oT0l3ME2tOk42OiCP	NIi5UWozOjN\|NkK0Oi=>
HCC2998	NFXYbHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\EcI9oT0l3ME2tOk4zQSCP	Mki0NlI{OzZ{NE[=
KM12	NGLxUJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVP2SoYydG:pR1m1NF0uPS55NjDN	Mn\rNlI{OzZ{NE[=
HT-29	NETReVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITud\|Rtd2eJSUWwQU03NjNyIF2=	NGTaeJYzOjN\|NkK0Oi=>
HCT15	Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUOxSJo6dG:pR1m1NF0uPi5zMjDN	MVqyNlM{PjJ2Nh?=
HCT116	M372Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjKcI9oT0l3ME2tOU45PyCP	NUXkTYpSOjJ\|M{[yOFY>
NCI-H23	NHvFe3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;BSY5td2eJSUWwQU02Njd\|IF2=	M1LMU\|IzOzN4MkS2
NCI-H226	M{LVW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fvXYxw\0eLNUC9MVYvOjFiTR?=	M1z6dlIzOzN4MkS2
NCI-H522	M4f3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXacI9oT0l3ME2tOk42QCCP	NET0VHUzOjN\|NkK0Oi=>
NCI-H483	NULwbHRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHXNnNkdG:pR1m1NF0uPi53NjDN	NInhSJUzOjN\|NkK0Oi=>
A549	NXfNOot5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjsc4dIUTVyPT22MlE2KE1?	MWmyNlM{PjJ2Nh?=
DMS273	M2LvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHricJZtd2eJSUWwQU03NjR\|IF2=	NXfzVFBrOjJ\|M{[yOFY>
DMS114	MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX25[mo4dG:pR1m1NF0uPS57MjDN	M{X0NFIzOzN4MkS2
LOXIMVI	MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPrcI9oT0l3ME2tOk4zQSCP	NInLPHUzOjN\|NkK0Oi=>
OVCAR3	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlW0cI9oT0l3ME2tOk44OSCP	NIDH[YQzOjN\|NkK0Oi=>
OVCAR4	NHzvZZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vvNYxw\0eLNUC9MVUvPzZiTR?=	MljjNlI{OzZ{NE[=
OVCAR5	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mle2cI9oT0l3ME2tOk4zPiCP	NWfSNndwOjJ\|M{[yOFY>
OVCAR8	NVTUUZkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\sc4dIUTVyPT21Mlc{KE1?	MYOyNlM{PjJ2Nh?=
SKOV3	NV;GUWRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLsc4dIUTVyPT22MlUzKE1?	NVH2RnZTOjJ\|M{[yOFY>
RXF631L	NVzQXZNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLEbmttd2eJSUWwQU03Njh6IF2=	MUSyNlM{PjJ2Nh?=
ACHN	MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEG4SWdtd2eJSUWwQU03NjB5IF2=	MYmyNlM{PjJ2Nh?=
St-4	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlT1cI9oT0l3ME2tOU42PiCP	NYS5ZlVYOjJ\|M{[yOFY>
MKN1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rVSYxw\0eLNUC9MVcvODhiTR?=	MXmyNlM{PjJ2Nh?=
MKN7	MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzsc4dIUTVyPT22MlUxKE1?	NWG2OpJ2OjJ\|M{[yOFY>
MKN28	M3K4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGG1V3htd2eJSUWwQU02NjV{IF2=	MnH3NlI{OzZ{NE[=
MKN45	NVTpdHlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjsc4dIUTVyPT22MlU2KE1?	NVXQW\|BoOjJ\|M{[yOFY>
MKN74	Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojLcI9oT0l3ME2tOk4xOiCP	NUX3cGxLOjJ\|M{[yOFY>
DU145	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjCT4ltd2eJSUWwQU02Njh3IF2=	NUHhdW91OjJ\|M{[yOFY>
PC3	NXztOItnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrlcI9oT0l3ME2tOk43PiCP	MoP0NlI{OzZ{NE[=
ES5	NULrUVNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;ETWM2OD13MD6yNUBvVQ>?	NH3TOFJUSU6JRWK=
HH	NHLBZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3oSHJKSzVyPUGxNU4xQCCwTR?=	NImzZXJUSU6JRWK=
MHH-PREB-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTFzND6zJI5O	NInkVm5USU6JRWK=
NCI-H1770	MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWH2cmQyUUN3ME2xNlMvQDZibl2=	MkjTV2FPT0WU
HuO9	M1nXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvITWM2OD1{ME[uNFIhdk1?	NYH0N5dvW0GQR1XS
HAL-01	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjRc\|lrUUN3ME2yNFYvPzNibl2=	M1v1fnNCVkeHUh?=
NOS-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHP6Wm1KSzVyPUKxNU45OiCwTR?=	NG\IUYZUSU6JRWK=
HGC-27	MoXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYT1PI14UUN3ME2yNVIvPTdibl2=	NX\2NnV{W0GQR1XS
NB69	NXSzSYhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGSzb2RKSzVyPUK0OU4zPyCwTR?=	MnTsV2FPT0WU
RS4-11	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrpTWM2OD1{NkGuO\|Yhdk1?	MmfaV2FPT0WU
DOK	NE\tZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnvSpJ5UUN3ME2zNFEvPyCwTR?=	MVTTRW5ITVJ?
LB2241-RCC	Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPD[oRIUUN3ME2zNFMvQDRibl2=	M4LBeXNCVkeHUh?=
NCI-H1623	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnteYNNUUN3ME2zNFQvODhibl2=	MmW3V2FPT0WU
YH-13	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTNyND6zNkBvVQ>?	M1HucnNCVkeHUh?=
BPH-1	NGjPWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{j3R2lEPTB;M{G0JI5O	MoPHV2FPT0WU
AN3-CA	MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;aTWM2OD1\|NECuN\|chdk1?	Mo\WV2FPT0WU
ES7	NHHEXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLxUpJ3UUN3ME2zOFEvQTlibl2=	M3ThfHNCVkeHUh?=
MDA-MB-175-VII	NYK3S2R1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XWXGlEPTB;M{WyMlkzKG6P	NW\1bVZWW0GQR1XS
GAMG	Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPqWVl7UUN3ME2zO\|AvQDVibl2=	MXPTRW5ITVJ?
CHL-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofsTWM2OD1\|N{iuOlUhdk1?	NV3jO5ZbW0GQR1XS
NB7	NGjZVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfoS29GUUN3ME2zPFkvQDNibl2=	NITHWFRUSU6JRWK=
MFE-280	Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\HOlRJUUN3ME20NVgvOiCwTR?=	MVLTRW5ITVJ?
HL-60	MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnxTWM2OD12MkWuO\|Uhdk1?	M{LSbnNCVkeHUh?=
GCIY	MkPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXjW2dKSzVyPUSzN{45KG6P	MoXHV2FPT0WU
MDA-MB-361	NHfIbIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWm2eFc6UUN3ME20N\|kvOTNibl2=	MmrTV2FPT0WU
LXF-289	M1TLb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnmTWM2OD12NEiuNlchdk1?	NFSxZ2lUSU6JRWK=
NBsusSR	NYH4WW4{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zOR2lEPTB;NEi4Mlg2KG6P	MmriV2FPT0WU
KU-19-19	Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHzTWM2OD13MU[uNFchdk1?	M1HIOnNCVkeHUh?=
A204	Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3i5XGlEPTB;NUKyMlM{KG6P	M2TCS3NCVkeHUh?=
LB1047-RCC	Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;zSXdKSzVyPUWyNk46OyCwTR?=	MY\TRW5ITVJ?
COLO-684	M{LiVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTV{Mz6xNUBvVQ>?	M4LGWXNCVkeHUh?=
PA-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnBeWFrUUN3ME21N\|IvPDFibl2=	NYrqNo9JW0GQR1XS
MG-63	M2HZdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLBem9KSzVyPUW0NU4yOSCwTR?=	NX23U3Z2W0GQR1XS
BHT-101	Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{OxV2lEPTB;NUS0Mlk1KG6P	NUL1cZY6W0GQR1XS
NKM-1	M{XNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGftb3hKSzVyPUW5N{4xQSCwTR?=	MV;TRW5ITVJ?
T47D	NEHFPVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTV7Nz61OkBvVQ>?	NV6zTJh[W0GQR1XS
MOLT-4	M3nVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\STWM2OD14MkOuOlIhdk1?	NV3jbYdCW0GQR1XS
IGROV-1	MlHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\v[XZKSzVyPU[zOE4{OSCwTR?=	MXjTRW5ITVJ?
ES4	NWfZZYo1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2T5e2lEPTB;NkO5MlU1KG6P	MlHjV2FPT0WU
HuO-3N1	M3e0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTZ2Mj6zPEBvVQ>?	MlzxV2FPT0WU
NEC8	MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTZ3Mz61O{BvVQ>?	MkH6V2FPT0WU
HO-1-N-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHy1c2NKSzVyPU[1PU4yPyCwTR?=	NV3JfYxLW0GQR1XS
EPCL-272H	Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LUcmlEPTB;Nki3MlIyKG6P	Mo\sV2FPT0WU
D-263MG	MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnKT2pXUUN3ME23NVgvOSCwTR?=	M{fTdnNCVkeHUh?=
MV-4-11	NXGyXoVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTd{ND6zNUBvVQ>?	MYPTRW5ITVJ?
SK-NEP-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTd{NT65OEBvVQ>?	NVLYTZZLW0GQR1XS
SW872	NXu0TJhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTd{Nz64PUBvVQ>?	NHvnRXNUSU6JRWK=
P30-OHK	NXmyc3V5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXsTWM2OD15M{CuO\|Ehdk1?	NHTLRm1USU6JRWK=
OMC-1	MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\j[WlEPTB;N{WxMlA6KG6P	MUPTRW5ITVJ?
LoVo	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjCVoxKSzVyPUe3O{46KG6P	MljpV2FPT0WU
LNCaP-Clone-FGC	NY\tVJV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vJfGlEPTB;N{m2MlM1KG6P	MXXTRW5ITVJ?
L-363	NFnFSZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInnSXBKSzVyPUe5PE41OiCwTR?=	NFXqelJUSU6JRWK=
ES8	NYjEeGVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\uZW1KSzVyPUixNE42OiCwTR?=	NIP3XZNUSU6JRWK=
697	NWjC[IxPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTSbIltUUN3ME24N\|EvPTVibl2=	MYfTRW5ITVJ?
HSC-3	M1nJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4n6R2lEPTB;OEO5MlU1KG6P	MnHBV2FPT0WU
H4	MoPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTh3MD64OUBvVQ>?	NFXkVmRUSU6JRWK=
QIMR-WIL	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3TZ5ZKSzVyPUi2OU4zKG6P	NGHOd2dUSU6JRWK=
OAW-42	MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\MO2poUUN3ME24O\|IvOTlibl2=	NFTWfHZUSU6JRWK=
MCF7	M2DrWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY[5U5VvUUN3ME24PVgvPTlibl2=	MnHWV2FPT0WU
SCC-25	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXuxZ28{UUN3ME25NVQvOTlibl2=	NXrDcVlvW0GQR1XS
NCI-H1563	NFTnRmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLvTWM2OD17MUWuPVkhdk1?	MXfTRW5ITVJ?
OVCAR-5	NEOydlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoD1TWM2OD17NECuNVchdk1?	MVzTRW5ITVJ?
HDLM-2	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTvWIpYUUN3ME25OFkvOiCwTR?=	NWDnd4d5W0GQR1XS
NB5	M1rUUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTl3Nj62JI5O	M3v2bnNCVkeHUh?=
NCI-H292	NEjrNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTl5ND6zNkBvVQ>?	MljWV2FPT0WU
A101D	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHj1cmlKSzVyPUm5NE4yQSCwTR?=	M{TtZ3NCVkeHUh?=
NCI-H1648	NFXZdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnSbJBKSzVyPUm5PE42OSCwTR?=	MlHZV2FPT0WU
EKVX	NYrDO5cxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWCwR2o1UUN3ME2xMlAyOjlizszN	MX\TRW5ITVJ?
SW1710	MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTFwMESyN\|Mh\|ryP	MmLQV2FPT0WU
WM-115	M37ZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LacWlEPTB;MT6wOlY2PiEQvF2=	M37pfnNCVkeHUh?=
CAL-54	NI\vZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLN[25KSzVyPUGuNFcxQDFizszN	NEO3WJlUSU6JRWK=
TGBC24TKB	NVzJ[Vk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlH3TWM2OD1zLkC4NFQ2KM7:TR?=	MVLTRW5ITVJ?
NCI-H520	NXXUcopnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrOU\|NKSzVyPUGuNFg6PjdizszN	M3[3bXNCVkeHUh?=
D-423MG	NInkZ\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHaS3VKSzVyPUGuNFk6PjJizszN	MmjwV2FPT0WU
BFTC-905	MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHU[ZBKSzVyPUGuNVM1PDlizszN	NH;MTJRUSU6JRWK=
HT	MnzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPvPGhKSzVyPUGuNVM1PzhizszN	MXjTRW5ITVJ?
CTB-1	M3\RV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTFwMUSyPVMh\|ryP	MWTTRW5ITVJ?
Hs-578-T	NVfFbnI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXIWY9KSzVyPUGuNVk2PjVizszN	MXjTRW5ITVJ?
HuH-7	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PNfGlEPTB;MT6yNFk1QSEQvF2=	NH7MXmdUSU6JRWK=
LB996-RCC	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHpTWM2OD1zLkKyNVc4KM7:TR?=	NUT2VJk4W0GQR1XS
KYSE-270	M1jLZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrCW41KSzVyPUGuNlk4OzRizszN	MnfzV2FPT0WU
A4-Fuk	M2XXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPzTWM2OD1zLkK5PVk{KM7:TR?=	Mm\xV2FPT0WU
A498	MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjyTWM2OD1zLkOwOFc1KM7:TR?=	M{fM[HNCVkeHUh?=
SK-MEL-1	NGjKO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXXTVhCUUN3ME2xMlMxPjd7IN88US=>	NEXOOmdUSU6JRWK=
AU565	M13ZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnMe4pKSzVyPUGuN\|E5PjNizszN	MkfPV2FPT0WU
Saos-2	NEntVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTFwM{OyNFUh\|ryP	M4rLdnNCVkeHUh?=
A549	NHLxVYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPoUZhkUUN3ME2xMlM6QTdizszN	NH\EUVJUSU6JRWK=
BFTC-909	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrZTWM2OD1zLkSzN\|A2KM7:TR?=	Mk\mV2FPT0WU
MDA-MB-415	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmmwTWM2OD1zLkS4OlkzKM7:TR?=	NYTDbm9XW0GQR1XS
639-V	M1LkfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;o[lNKSzVyPUGuOVAzPDVizszN	M3rB[HNCVkeHUh?=
A704	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPic3ZYUUN3ME2xMlUxPzh3IN88US=>	M{Tl[3NCVkeHUh?=
PANC-03-27	Mk[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTFwNUG0NFgh\|ryP	MXHTRW5ITVJ?
SK-MEL-28	Mn7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPydVRlUUN3ME2xMlU3ODh3IN88US=>	M4LVTHNCVkeHUh?=
Ramos-2G6-4C10	NHHtbo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHKWZdqUUN3ME2xMlYxPzR4IN88US=>	NFfIVIpUSU6JRWK=
HuP-T4	NIryW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;0TWM2OD1zLk[wO\|c5KM7:TR?=	M135ZnNCVkeHUh?=
VA-ES-BJ	NXvx[IpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\RUWlEPTB;MT62NVI4KM7:TR?=	M3PLV3NCVkeHUh?=
EFM-19	M4G2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PSUmlEPTB;MT62NVgyKM7:TR?=	MnjQV2FPT0WU
G-401	MmizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rWN2lEPTB;MT62NlE3PCEQvF2=	NFXqXnVUSU6JRWK=
D-566MG	M3fr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DBbmlEPTB;MT62NlU{KM7:TR?=	MVvTRW5ITVJ?
JVM-3	NEfI[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlm5TWM2OD1zLk[0PFc2KM7:TR?=	NUewfYJoW0GQR1XS
TK10	NXjHfpRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;rZ2lEPTB;MT62O\|A5OyEQvF2=	NETjOmhUSU6JRWK=
BT-20	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTFwNki5NFIh\|ryP	Mln0V2FPT0WU
EGI-1	NIn1cIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTFwOES3NFEh\|ryP	MVvTRW5ITVJ?
EW-16	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPnRVBRUUN3ME2xMlg2OTh{IN88US=>	MWHTRW5ITVJ?
NCI-H2228	NXHmfFVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3QTWM2OD1zLki1NlA{KM7:TR?=	NF[weHJUSU6JRWK=
BB49-HNC	M1naNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPOeVNKSzVyPUGuPFg3QTJizszN	M1PkfHNCVkeHUh?=
G-402	NH7wclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGe0SndKSzVyPUGuPFk4QTdizszN	M{ToPXNCVkeHUh?=
NCI-H526	NHfhS\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWO1NZNYUUN3ME2xMlkyOzlizszN	MYLTRW5ITVJ?
ME-180	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\JTWM2OD1zLkmzOFc4KM7:TR?=	NV;FeXRFW0GQR1XS
PFSK-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPOTWM2OD1zLkm0OFU5KM7:TR?=	NHHhd4lUSU6JRWK=
TYK-nu	MlvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTFwOUW4NlMh\|ryP	NELob\|BUSU6JRWK=
HOS	M4THNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTFwOUe5OFgh\|ryP	NGLObnBUSU6JRWK=
T98G	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnRTWM2OD1zLkm5NFA3KM7:TR?=	MULTRW5ITVJ?
SK-MES-1	MoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXSxc21qUUN3ME2yMlAyOzN{IN88US=>	NYL6fI9{W0GQR1XS
SNB75	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTwTWM2OD1{LkCxOVQyKM7:TR?=	Mo\xV2FPT0WU
LAMA-84	NH7ifFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M120bWlEPTB;Mj6wNlY5QSEQvF2=	MmLjV2FPT0WU
CAL-39	MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTk[WxKSzVyPUKuNFMzQCEQvF2=	NGXo[XpUSU6JRWK=
LOXIMVI	NUDHZoNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDBWFhKSzVyPUKuNFQxQDRizszN	NIPP[ndUSU6JRWK=
NH-12	NGLSSFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnGcpZIUUN3ME2yMlA2PDJ2IN88US=>	MW\TRW5ITVJ?
NCI-H1048	NXHsVod7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\sVGlEPTB;Mj6xNFUzKM7:TR?=	NGjORmpUSU6JRWK=
KS-1	NIfibFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TB[2lEPTB;Mj6xNVAxOSEQvF2=	M3WzfXNCVkeHUh?=
NCI-N87	MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTJwMUOzPFQh\|ryP	M4fI[HNCVkeHUh?=
CHP-212	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHm3eWJKSzVyPUKuNVg1PDJizszN	M13nW3NCVkeHUh?=
HCC1419	MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jDNGlEPTB;Mj6yNVEyPSEQvF2=	NIL6W3hUSU6JRWK=
ES1	Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\VTWM2OD1{LkKxN\|I3KM7:TR?=	MmXkV2FPT0WU
NCI-H2030	M4P0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTJwMkSxNlMh\|ryP	M1:0THNCVkeHUh?=
EW-22	NGLZbI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4nPUGlEPTB;Mj6yOVA3PyEQvF2=	MXvTRW5ITVJ?
A431	M3rifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PRdGlEPTB;Mj6yO\|M2PCEQvF2=	MmfNV2FPT0WU
SF126	MkfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHWfm9DUUN3ME2yMlMxPjJ3IN88US=>	MmDyV2FPT0WU
SF295	MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3JTWM2OD1{LkOxOVI1KM7:TR?=	M2\E[HNCVkeHUh?=
D-502MG	MnjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTJwM{K0OlEh\|ryP	M4XNW3NCVkeHUh?=
HCC2157	NV\CTIRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3STWM2OD1{LkOyPVI4KM7:TR?=	NXfoSXF3W0GQR1XS
D-283MED	M3jBPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1v0UmlEPTB;Mj6zOVkzPiEQvF2=	M1zG[HNCVkeHUh?=
SNU-423	M{LP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPFdZVKSzVyPUKuOFAyPzFizszN	NEj3cGdUSU6JRWK=
SK-LU-1	NGLFWlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnMZoFKSzVyPUKuOFQ2QDZizszN	MWPTRW5ITVJ?
22RV1	NFvZOFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkThTWM2OD1{LkS1OlE4KM7:TR?=	NWH6U486W0GQR1XS
SW1088	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjUcW1rUUN3ME2yMlQ6OjF\|IN88US=>	MWHTRW5ITVJ?
HT-3	NEPySYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXESYJLUUN3ME2yMlQ6OjV7IN88US=>	NFXTb2hUSU6JRWK=
NCI-H1666	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonjTWM2OD1{LkWxNVA1KM7:TR?=	MYLTRW5ITVJ?
EM-2	NFXN[\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofMTWM2OD1{LkWxNVY6KM7:TR?=	MYLTRW5ITVJ?
SNU-449	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTJwNUewNVQh\|ryP	MWDTRW5ITVJ?
786-0	NEPi[FJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M12zOmlEPTB;Mj61PVI{QCEQvF2=	M3;KbHNCVkeHUh?=
SKG-IIIa	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLhTWM2OD1{Lk[1PVM6KM7:TR?=	MXzTRW5ITVJ?
MEL-HO	NXrWV2pXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HYVWlEPTB;Mj62O\|Y{PCEQvF2=	NULaO4FFW0GQR1XS
LCLC-97TM1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLIZmRKSzVyPUKuOlkzPjdizszN	NVrzVJdXW0GQR1XS
MKN7	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTJwN{C3OVQh\|ryP	MlfwV2FPT0WU
5637	M4HvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLGR21KSzVyPUKuO\|ExOzVizszN	MUnTRW5ITVJ?
HOP-92	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DYRWlEPTB;Mj63OFcyPyEQvF2=	NWnJVHh[W0GQR1XS
MDA-MB-157	M3vGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTJwOEKwNlMh\|ryP	Ml7sV2FPT0WU
NB12	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTJwOES5NVQh\|ryP	NYDHdGhkW0GQR1XS
DMS-273	MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;mfINKSzVyPUKuPFY1PyEQvF2=	NVW5PZk{W0GQR1XS
HCC70	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17YUmlEPTB;Mj64OlU5QSEQvF2=	NHXxW5ZUSU6JRWK=
YKG-1	M2fl[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rw[mlEPTB;Mz6wN\|c5PyEQvF2=	MnznV2FPT0WU
NCI-H28	NVHOSZZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTNwMEWyPVEh\|ryP	NXfaUXNuW0GQR1XS
HN	NGPZWnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH6zZ3hKSzVyPUOuNFY3OzZizszN	M4[5cXNCVkeHUh?=
HT-1080	MnToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvtb4d{UUN3ME2zMlA5PjB4IN88US=>	NFHueVhUSU6JRWK=
HPAF-II	Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnKOo1tUUN3ME2zMlExODZ6IN88US=>	M4rpWnNCVkeHUh?=
U-2-OS	Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGW5UnRKSzVyPUOuNVM4QDJizszN	NFPWT2dUSU6JRWK=
SNU-387	M1PoSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnrfFFXUUN3ME2zMlE3OzZ2IN88US=>	MnW5V2FPT0WU
Becker	M3e4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTNwMU[4NFgh\|ryP	NVTXUGhPW0GQR1XS
BHY	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTNwMkW1O\|Eh\|ryP	MVfTRW5ITVJ?
HTC-C3	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLBTWM2OD1\|LkK5N\|UzKM7:TR?=	M1\3R3NCVkeHUh?=
M14	MmXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTNwM{C2OlMh\|ryP	M4C4OnNCVkeHUh?=
COR-L23	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkL4TWM2OD1\|LkO3Nlc6KM7:TR?=	NIT1S4ZUSU6JRWK=
C32	NIfCcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn6xTWM2OD1\|LkSxOVA5KM7:TR?=	MkjvV2FPT0WU
Mewo	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLBTWM2OD1\|LkSyNVgzKM7:TR?=	MmnhV2FPT0WU
TE-8	NXjYT3J4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XEfGlEPTB;Mz60PFI2QSEQvF2=	M4D4XnNCVkeHUh?=
RPMI-2650	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rVVGlEPTB;Mz62NFY{PyEQvF2=	M{TuNXNCVkeHUh?=
AGS	MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17aSWlEPTB;Mz62NlQ3PCEQvF2=	MVzTRW5ITVJ?
MZ2-MEL	MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUj5S3BXUUN3ME2zMlY3OTN6IN88US=>	M3y2VXNCVkeHUh?=
Calu-3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTNwN{GyPFch\|ryP	M4DkNHNCVkeHUh?=
SJSA-1	NX7BdXVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTNwN{GzNVUh\|ryP	M{T1SHNCVkeHUh?=
SW962	Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfTTWM2OD1\|LkeyOlM3KM7:TR?=	NGTNVHFUSU6JRWK=
PC-14	MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnHTWM2OD1\|LkezNlIzKM7:TR?=	MYPTRW5ITVJ?
SW1573	MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3mTWM2OD1\|Lke1N\|Q5KM7:TR?=	MnG5V2FPT0WU
769-P	MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXL6dIR6UUN3ME2zMlgzPzR\|IN88US=>	NV[5S4hVW0GQR1XS
KNS-62	NF\NU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVO5do5YUUN3ME2zMlkzOzN6IN88US=>	Mn;xV2FPT0WU
NCI-H747	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTRwMEW2N\|gh\|ryP	NHrWXW1USU6JRWK=
LN-405	MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHi[GEzUUN3ME20MlE2PzJ6IN88US=>	NVzlelRkW0GQR1XS
OVCAR-8	M{DNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmX2TWM2OD12LkKyOVQ{KM7:TR?=	NY\qXpVFW0GQR1XS
DMS-114	M33uc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXG3bYF4UUN3ME20MlI{QDlzIN88US=>	MYLTRW5ITVJ?
NCI-H2126	NGn3R5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7XTWM2OD12LkK0OVU5KM7:TR?=	NG[ydYZUSU6JRWK=
TCCSUP	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3z1ZmlEPTB;ND6yOFc5QCEQvF2=	M3\4dHNCVkeHUh?=
SK-N-FI	NXziepdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{GwbmlEPTB;ND6yOVM{OiEQvF2=	NWPPN3BVW0GQR1XS
HCE-4	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvsTWM2OD12LkK3NVk4KM7:TR?=	MU\TRW5ITVJ?
DK-MG	MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljrTWM2OD12LkOwN\|kh\|ryP	NHTGRldUSU6JRWK=
RO82-W-1	NWDMXIRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjsTWM2OD12LkOyOVg1KM7:TR?=	NWf0dphPW0GQR1XS
A2780	M2r6W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTRwM{[2PFIh\|ryP	M3O1VnNCVkeHUh?=
ETK-1	NGXYcpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUexOoY1UUN3ME20MlM4ODV{IN88US=>	M2fj[3NCVkeHUh?=
FADU	NIXTSmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjQbJdKSzVyPUSuN\|c1PjdizszN	NFPRcnBUSU6JRWK=
CAL-12T	M1GwUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1OwV2lEPTB;ND60NVQyOyEQvF2=	NVTVUZdLW0GQR1XS
647-V	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfGRVhUUUN3ME20MlQ1ODJ{IN88US=>	NFWwUXFUSU6JRWK=
TGBC1TKB	M4XiNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTpTWM2OD12LkS1NVE{KM7:TR?=	M33OXnNCVkeHUh?=
LU-99A	NWnYUHk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2iwZmlEPTB;ND60OlA3KM7:TR?=	NYrnZ4pIW0GQR1XS
CAL-33	NFf4NWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTRwNUK0OVYh\|ryP	NWC4ZZM2W0GQR1XS
LU-134-A	NHPtS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vaUGlEPTB;ND61Nlc1PSEQvF2=	MVTTRW5ITVJ?
NCI-H1355	MmHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGr6bnlKSzVyPUSuOVUyPDZizszN	MX\TRW5ITVJ?
RPMI-7951	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW[4RlJ5UUN3ME20MlU4ODB{IN88US=>	NE\1cWdUSU6JRWK=
TE-1	MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LKVGlEPTB;ND62OlE1OyEQvF2=	Mm[1V2FPT0WU
OE33	MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDW[ZpKSzVyPUSuO\|A2OTFizszN	Mom4V2FPT0WU
CAL-51	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPrd45SUUN3ME20MlcyODh{IN88US=>	M13lNHNCVkeHUh?=
SW1783	M1fr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTyTWM2OD12Lke1N\|A5KM7:TR?=	MULTRW5ITVJ?
BT-474	NXnBUmw3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLPTWM2OD12Lke2N\|g1KM7:TR?=	M1flUnNCVkeHUh?=
KYSE-520	NVfFZpAyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTPcGIyUUN3ME20Mlg4Ozl{IN88US=>	MkLGV2FPT0WU
8-MG-BA	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3L6NmlEPTB;ND64PFU2PyEQvF2=	MYfTRW5ITVJ?
IA-LM	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XaXmlEPTB;ND65PVQ{PSEQvF2=	M{XzfHNCVkeHUh?=
SW954	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;DbphKSzVyPUSuPVk1PDNizszN	NX\MZmQ3W0GQR1XS
RPMI-8226	NYHDd3RYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHr4ZXhKSzVyPUWuNFU1PjFizszN	M3q0dHNCVkeHUh?=
MKN1	NWO1VJAyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fOR2lEPTB;NT6wO\|kzPyEQvF2=	MV\TRW5ITVJ?
A375	NXnRTWlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LYSGlEPTB;NT6wPVI2PiEQvF2=	M4TXbHNCVkeHUh?=
8305C	MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfxfWdKSzVyPUWuNFk5QDdizszN	MVXTRW5ITVJ?
CAL-62	Mkj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYToVlh3UUN3ME21MlE5OjV7IN88US=>	NELKdlNUSU6JRWK=
NB10	NUPlb2k1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTVwMkK3OFQh\|ryP	MoXhV2FPT0WU
OC-314	M3LsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPhOJVKSzVyPUWuN\|c1PDRizszN	NFjQfFFUSU6JRWK=
PSN1	MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrUXnRtUUN3ME21MlM5Ojh4IN88US=>	M3exbHNCVkeHUh?=
GR-ST	M2O3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTVwM{izNlIh\|ryP	NI\WfWVUSU6JRWK=
P12-ICHIKAWA	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\N[pJKSzVyPUWuOFAyKM7:TR?=	NV21U3BLW0GQR1XS
NCI-H1092	NIO1dnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2O1NmlEPTB;NT60NVE1QCEQvF2=	NV35XWhyW0GQR1XS
SCC-4	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWq4[HA3UUN3ME21MlQyOzV3IN88US=>	Mm\IV2FPT0WU
TE-6	NWKzOHEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7SO4RKSzVyPUWuOFE5OTZizszN	M3\vfnNCVkeHUh?=
DOHH-2	NWiyU495T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF[wRZFKSzVyPUWuOFIzPDhizszN	Ml;RV2FPT0WU
SW684	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknqTWM2OD13Lk[2N\|g2KM7:TR?=	NEfKe4tUSU6JRWK=
CP50-MEL-B	NHT4XHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TOUGlEPTB;NT62PFY5PCEQvF2=	NWfrb4tDW0GQR1XS
UM-UC-3	MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rWc2lEPTB;NT63NlI{OSEQvF2=	M3T3Z3NCVkeHUh?=
LC-2-ad	NV:xTpliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HrRmlEPTB;NT63PFI2OSEQvF2=	NV\JUnF6W0GQR1XS
PC-3	M37QOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTVwOUG2NVUh\|ryP	NEnLNndUSU6JRWK=
CAN	NFTKdIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGL3WmtKSzVyPUWuPVI5OiEQvF2=	NVi3dlhXW0GQR1XS
ESS-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XXW2lEPTB;NT65O\|g3QSEQvF2=	M{PzfnNCVkeHUh?=
ATN-1	NHXzfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfRXJhCUUN3ME22MlA2PTZ6IN88US=>	MVzTRW5ITVJ?
BxPC-3	Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUO3O3BlUUN3ME22MlA5OjF7IN88US=>	M2HJdXNCVkeHUh?=
KYSE-150	NFqx[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTZwMUK0O\|Yh\|ryP	MYjTRW5ITVJ?
RPMI-8866	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLlTWM2OD14LkG5NVY{KM7:TR?=	M4nkPHNCVkeHUh?=
SW780	NHmyOpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jOVGlEPTB;Nj6yNFQzKM7:TR?=	MXzTRW5ITVJ?
A388	MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mor1TWM2OD14LkKzNVE2KM7:TR?=	M2XaZXNCVkeHUh?=
NCI-H1437	MlPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrTTWM2OD14LkK0NFc{KM7:TR?=	NGfTU45USU6JRWK=
NCI-H1755	NY[5Tm9wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPGTWM2OD14LkO2OlEzKM7:TR?=	MVnTRW5ITVJ?
LS-123	NYfqbXhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHUTWM2OD14LkSwOVIyKM7:TR?=	M2jqbnNCVkeHUh?=
CaR-1	NYjOPVU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LlOWlEPTB;Nj60OlM4OyEQvF2=	NGW2WHBUSU6JRWK=
RT-112	MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTZwNkCzN\|gh\|ryP	MkXiV2FPT0WU
CGT	NHPwO\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTZwN{O2PFEh\|ryP	NEnpOXVUSU6JRWK=
SW626	MmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTZwN{O5OFYh\|ryP	NF2zSlVUSU6JRWK=
AsPC-1	NV;SepB6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTZwN{S1NFch\|ryP	NFPNb\|lUSU6JRWK=
SBC-5	NWfaOWxUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjtcYxXUUN3ME22Mlk4Ojl5IN88US=>	MlXQV2FPT0WU
SF539	MoPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\ieGZsUUN3ME22Mlk6OzN\|IN88US=>	MYDTRW5ITVJ?
TI-73	NWrCUINvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHGb5FiUUN3ME23MlA3Ojh3IN88US=>	M1XBSnNCVkeHUh?=
MHH-ES-1	MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\G[2lEPTB;Nz6wO\|c3OiEQvF2=	NUfWO2R3W0GQR1XS
KYSE-510	NF7ZSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HkOWlEPTB;Nz6wPFQ{OiEQvF2=	NWXISmllW0GQR1XS
EW-1	MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTdwM{[5PVYh\|ryP	MVHTRW5ITVJ?
SK-OV-3	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTdwM{m0N\|Ih\|ryP	NF;Zc\|JUSU6JRWK=
MC-IXC	M1r6NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfrTWM2OD15LkSxPVczKM7:TR?=	NFLzTodUSU6JRWK=
HSC-2	Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fDS2lEPTB;Nz60NlcxPSEQvF2=	NVLkT\|RJW0GQR1XS
NCI-H2342	NVrOenZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVn4SI13UUN3ME23MlUyPDlizszN	MXTTRW5ITVJ?
NCI-H1792	NF2yeYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\XenNLUUN3ME23MlUyPzFzIN88US=>	NHvlU41USU6JRWK=
HT-1376	Mn\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTdwOEe3O\|gh\|ryP	NVPETJdKW0GQR1XS
EW-13	MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfLWJYxUUN3ME23Mlg6QTd5IN88US=>	NX3rNVVJW0GQR1XS
no-11	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTdwOUCxO\|Qh\|ryP	MYLTRW5ITVJ?
Daoy	M3vtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHLc5lKSzVyPUeuPVQ{OjFizszN	NYTiUpFHW0GQR1XS
COLO-800	NUnaZZJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7xTWM2OD16LkC0NVYzKM7:TR?=	NUXTR2VJW0GQR1XS
GB-1	NHHURmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTWTWM2OD16LkC2OVY2KM7:TR?=	M37IR3NCVkeHUh?=
SJRH30	NUGzfGFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTYTWM2OD16LkG1PFc5KM7:TR?=	NW\0UWxbW0GQR1XS
NCI-H2291	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\od2lEPTB;OD6yPVE5PyEQvF2=	M4LkZnNCVkeHUh?=
J82	NV;2OFY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRThwMkm0PVEh\|ryP	NGi4U4FUSU6JRWK=
NCI-H596	NX25emN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXETWM2OD16LkOxOFU{KM7:TR?=	MlyyV2FPT0WU
RERF-LC-MS	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfVT\|FKSzVyPUiuN\|Q5PTZizszN	Ml3yV2FPT0WU
RH-18	NU\lS3RxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRThwM{WwOFYh\|ryP	MojaV2FPT0WU
SW48	NFvsXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTXRYhFUUN3ME24MlU6PDV\|IN88US=>	M{LBfHNCVkeHUh?=
RD	M1fFSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkKxTWM2OD16LkW5N\|kyKM7:TR?=	MY\TRW5ITVJ?
MS-1	NHS1VmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRThwNkGzPFch\|ryP	MXjTRW5ITVJ?
ES6	Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vVVWlEPTB;OD63N\|EyQSEQvF2=	M125cnNCVkeHUh?=
TE-12	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRThwN{e1NFUh\|ryP	Mnu3V2FPT0WU
DBTRG-05MG	NGS3W2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRThwOUGyNVch\|ryP	MXjTRW5ITVJ?
KINGS-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojwTWM2OD16LkmyPVM5KM7:TR?=	MmLCV2FPT0WU
HLE	MnvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfkTWM2OD16LkmzO\|g2KM7:TR?=	MkLsV2FPT0WU
MHH-NB-11	NVzGRm1DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnKTWM2OD17LkCxPFM6KM7:TR?=	MkCxV2FPT0WU
U-87-MG	M2f4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTTUWVUUUN3ME25MlI1OzJzIN88US=>	MXzTRW5ITVJ?
MN-60	NXPt[3kxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vhSWlEPTB;OT6yOFU1OiEQvF2=	Mof6V2FPT0WU
SAS	Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjqdWVDUUN3ME25MlI2PThzIN88US=>	MU\TRW5ITVJ?
NCI-H446	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlX2TWM2OD17LkO2NUDPxE1?	NG[5bVNUSU6JRWK=
C-33-A	NV3hZ\|M6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjCVXlKSzVyPUmuOFM6QDhizszN	MmK5V2FPT0WU
RXF393	NFL3ZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLTTWM2OD17LkS3NFAzKM7:TR?=	NUXIXnB7W0GQR1XS
CGTH-W-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVT0S\|hCUUN3ME25MlQ6Ozh2IN88US=>	Mn7rV2FPT0WU
RCM-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTlwNkO4NFEh\|ryP	MknLV2FPT0WU
SN12C	NV7RN3lOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXwTld1UUN3ME25MlY2OzN6IN88US=>	M1z1ZXNCVkeHUh?=
KLE	M33PSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonDTWM2OD17LkewNFA6KM7:TR?=	Mmr5V2FPT0WU
EFO-21	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLpTWM2OD17Lke3N\|gzKM7:TR?=	MWnTRW5ITVJ?
KYSE-70	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHr0d4RKSzVyPUmuPFgxOTFizszN	Mlm2V2FPT0WU
D-247MG	NV3EVWZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\SeFd5UUN3ME2xNE4xPTZ6IN88US=>	NFrCeWlUSU6JRWK=
MPP-89	NWn1bYl5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXwTWM2OD1zMD6wPVQ3KM7:TR?=	MXPTRW5ITVJ?
RVH-421	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPY[4pKSzVyPUGwMlE2ODVizszN	NGPvZYtUSU6JRWK=
NCI-H460	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmSwTWM2OD1zMD6yPFA3KM7:TR?=	NF\TO3VUSU6JRWK=
NOMO-1	NUK5VGJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\3eWlEPTB;MUCuN\|U{OiEQvF2=	NVz1N4ZRW0GQR1XS
DEL	NXXSUWM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHniPXlKSzVyPUGwMlM4QTRizszN	NV3wfGlQW0GQR1XS
HT55	NID1PFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH60W2xKSzVyPUGwMlYzODVizszN	NWrtRZZMW0GQR1XS
MC116	NEjMeI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fhVGlEPTB;MUCuOlY2PSEQvF2=	NHfBSY1USU6JRWK=
BB30-HNC	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHRdYZoUUN3ME2xNE43PjlizszN	MoHIV2FPT0WU
DJM-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nyS2lEPTB;MUCuOlk1QSEQvF2=	NGju[FRUSU6JRWK=
ZR-75-30	NUiwNlZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjMTWM2OD1zMD65OFQyKM7:TR?=	NF7CbW5USU6JRWK=
U-118-MG	M1jyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33iNWlEPTB;MUCuPVg6PiEQvF2=	M4TMR3NCVkeHUh?=
MSTO-211H	NFvMNo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXlTWM2OD1zMT6wO\|E3KM7:TR?=	M13YSXNCVkeHUh?=
SW837	NGe4XmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37sVmlEPTB;MUGuNFk1QSEQvF2=	NHzSfpNUSU6JRWK=
HuCCT1	NG\4[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlzyTWM2OD1zMT6xNlgyKM7:TR?=	NGXUb2xUSU6JRWK=
RCC10RGB	MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPx[\|NOUUN3ME2xNU4yOzVizszN	NGHweWhUSU6JRWK=
NMC-G1	M1\MVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzwbIlOUUN3ME2xNU4yPDl\|IN88US=>	NXnVVZBLW0GQR1XS
NCI-H650	NUH5Rld6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrwPVNKSzVyPUGxMlM4QTRizszN	MkLsV2FPT0WU
HEC-1	M3LGW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTFzLkSzNlgh\|ryP	MVnTRW5ITVJ?
DU-4475	M1zwUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTFzLkezPVMh\|ryP	MkDXV2FPT0WU
DSH1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjDTWM2OD1zMT63OlA3KM7:TR?=	MnLiV2FPT0WU
HCC1569	NXvUSHRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTFzLke2O\|gh\|ryP	M2CxR3NCVkeHUh?=
HCC1187	NXHSbpp4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofQTWM2OD1zMT64OVg5KM7:TR?=	NHzWNmpUSU6JRWK=
EW-11	M2LVZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTFzLkm0O\|Qh\|ryP	MYfTRW5ITVJ?
LB2518-MEL	M1\1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTF{LkC1PUDPxE1?	MYXTRW5ITVJ?
KALS-1	M176fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX70epNFUUN3ME2xNk45PTV\|IN88US=>	MWfTRW5ITVJ?
8505C	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGOyb2hKSzVyPUGyMlg5PSEQvF2=	M1XrU3NCVkeHUh?=
SK-N-DZ	M4DOOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVi1cHU{UUN3ME2xN{4xPDV\|IN88US=>	NHHpZ45USU6JRWK=
CHP-134	MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1m4WmlEPTB;MUOuNVE2QCEQvF2=	NULmWGRuW0GQR1XS
HCE-T	NVKwTFBoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HlU2lEPTB;MUOuNlM3PCEQvF2=	NFfudWxUSU6JRWK=
LB-831-BLC	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjEc2xWUUN3ME2xN{43OjR4IN88US=>	NYL2NGJUW0GQR1XS
OVCAR-4	MlHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;menJKSzVyPUGzMlY2OjRizszN	MluwV2FPT0WU
SW756	NUHydFk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDF[4tkUUN3ME2xN{44OjR4IN88US=>	M4THSnNCVkeHUh?=
OCUB-M	MoTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PtXGlEPTB;MUOuPFE2PiEQvF2=	MWXTRW5ITVJ?
SW982	NYjDfYlHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mor6TWM2OD1zMz64Nlc3KM7:TR?=	MlnOV2FPT0WU
DB	M4K5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGixfoxKSzVyPUGzMlg{QDRizszN	MkDIV2FPT0WU
H-EMC-SS	NWLXOoQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTF\|LkmxN\|kh\|ryP	NFHn[FhUSU6JRWK=
VMRC-RCZ	M37MTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvGUVFKSzVyPUG0MlAxOTVizszN	MojnV2FPT0WU
CAKI-1	MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHZTWM2OD1zND6wNVMzKM7:TR?=	NVvmXY9HW0GQR1XS
GI-1	NYGwbFZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fqV2lEPTB;MUSuNFY2QCEQvF2=	NV7iSnJNW0GQR1XS
Ca9-22	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFT1clJKSzVyPUG0MlYxPTRizszN	Mo[zV2FPT0WU
TE-5	NXjMXGR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXn0[FNwUUN3ME2xOE44OjB6IN88US=>	MnPiV2FPT0WU
EFO-27	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVn1dnFtUUN3ME2xOE44PjJ{IN88US=>	MXHTRW5ITVJ?
CAL-72	NIPnTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rZUmlEPTB;MUSuO\|c5OyEQvF2=	NFjCW2JUSU6JRWK=
GP5d	NILCb2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MornTWM2OD1zNT6wOFc1KM7:TR?=	Mnq5V2FPT0WU
CAS-1	MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nOVGlEPTB;MUWuNFY3KM7:TR?=	MUXTRW5ITVJ?
A2058	M4XY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTF3LkW2N\|gh\|ryP	NWLaeJRwW0GQR1XS
PANC-08-13	NV3Qflg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTF3Lk[4OVkh\|ryP	MkTqV2FPT0WU
Detroit562	M1P1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLXeoRlUUN3ME2xOU46OTN7IN88US=>	NGW5OXZUSU6JRWK=
PANC-10-05	MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnBTWM2OD1zNj6wPFIyKM7:TR?=	NYTnNVRNW0GQR1XS
KOSC-2	NVHicmNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\Md2lEPTB;MU[uNVEzPSEQvF2=	NWH5eIhOW0GQR1XS
GT3TKB	NXu5RoZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DBPGlEPTB;MU[uNVk5OSEQvF2=	NV[zeG4{W0GQR1XS
KM-H2	NEPSVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjUXI1KSzVyPUG2MlM3PDZizszN	MV3TRW5ITVJ?
LB771-HNC	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULnOlBXUUN3ME2xOk41PDJ{IN88US=>	M{D2dnNCVkeHUh?=
SF268	NYTS[Y9nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfxWpNKSzVyPUG2MlQ2OiEQvF2=	MYjTRW5ITVJ?
OE19	NXjySmZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7jTWM2OD1zNj61NlQh\|ryP	NV\sWmZ2W0GQR1XS
MLMA	NVjUZW1kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTF4LkW1O\|Eh\|ryP	M{nXc3NCVkeHUh?=
MDA-MB-231	NX;jRZU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfnTG9VUUN3ME2xOk44OTN4IN88US=>	NHrB[FFUSU6JRWK=
TGW	NGD1WZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;tcJhzUUN3ME2xOk45OTB{IN88US=>	MnqyV2FPT0WU
MDA-MB-453	MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{P4WmlEPTB;MUeuNFAxOyEQvF2=	M4j1PHNCVkeHUh?=
SNU-C2B	NEXJcZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTuPGczUUN3ME2xO{4xOjN5IN88US=>	MX;TRW5ITVJ?
A427	M1vwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTF5LkKzN\|Qh\|ryP	NX3tZ2lPW0GQR1XS
SK-MEL-2	Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYK2fJU4UUN3ME2xO{4{OjF\|IN88US=>	M2LYbXNCVkeHUh?=
KURAMOCHI	NXuy[2x1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zY[GlEPTB;MUeuN\|g6PyEQvF2=	NFPLN2ZUSU6JRWK=
IST-MEL1	MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrPS2wxUUN3ME2xO{46OTh{IN88US=>	NXLjT2JsW0GQR1XS
NCI-H1793	M1KyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rycmlEPTB;MUiuNVU5OSEQvF2=	NHjme\|RUSU6JRWK=
HCC1395	NHnLW3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTnOppHUUN3ME2xPE42PjFzIN88US=>	M3rCdHNCVkeHUh?=
NUGC-3	M17jT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XNb2lEPTB;MUiuOlU5PCEQvF2=	MoPQV2FPT0WU
BB65-RCC	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTF6Lk[2PUDPxE1?	MUPTRW5ITVJ?
RMG-I	M4DLcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jKWGlEPTB;MUiuO\|M5OiEQvF2=	MYHTRW5ITVJ?
LS-513	NHX0XIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTF6LkmyNlgh\|ryP	M121THNCVkeHUh?=
MFM-223	NUTWSIl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XEb2lEPTB;MUmuNFcyPiEQvF2=	NVLkOIJVW0GQR1XS
NCI-H727	MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHJVmpKSzVyPUG5MlMzQTVizszN	NGX0W4tUSU6JRWK=
KP-4	MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrkTWM2OD1zOT64OVMyKM7:TR?=	MX\TRW5ITVJ?
NB13	NIfuSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDITWM2OD1zOT64PFM6KM7:TR?=	MX7TRW5ITVJ?
UACC-893	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\ifoRKSzVyPUG5Mlk4PTdizszN	MoHrV2FPT0WU
HT-1197	NYLYPHlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPmOppKSzVyPUKwMlI6PThizszN	NVfneGZsW0GQR1XS
NCI-H2029	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTJyLkOyOlYh\|ryP	NHTS[opUSU6JRWK=
GI-ME-N	NVHpbZZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTJyLkOzO\|Mh\|ryP	Mnq0V2FPT0WU
OVCAR-3	NWHj[WNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnkSoFKSzVyPUKwMlU5OjJizszN	NFjUbppUSU6JRWK=
HD-MY-Z	MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHQTWM2OD1{MT6zOlk3KM7:TR?=	NYrndXZZW0GQR1XS
NTERA-S-cl-D1	MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HJdGlEPTB;MkGuOlczOiEQvF2=	Mlf1V2FPT0WU
SCH	NHvBcYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVS1SpB1UUN3ME2yNk41QTZizszN	NHX1PG5USU6JRWK=
KARPAS-299	M4T1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLVZmNKSzVyPUKzMlM5QDdizszN	M3zDb3NCVkeHUh?=
NCI-H1650	M{jFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmrsTWM2OD1{Mz65NlQyKM7:TR?=	NHKwUoRUSU6JRWK=
ACHN	M4L1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;LXWlEPTB;MkSuOFY2PiEQvF2=	MXXTRW5ITVJ?
M059J	MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrpe2QxUUN3ME2yOE42PjN2IN88US=>	NXvqVpZvW0GQR1XS
AM-38	MnrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PvTWlEPTB;MkWuOFgyKM7:TR?=	MYjTRW5ITVJ?
KG-1	NEjhTmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2i3OWlEPTB;MkWuOVQ6PCEQvF2=	NHfiN2RUSU6JRWK=
COLO-824	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLtT5dKSzVyPUK1MlU2QTlizszN	NGqxelhUSU6JRWK=
NCI-H1155	M{nCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrneJhnUUN3ME2yOU42QDR5IN88US=>	MkDTV2FPT0WU
NCI-H441	MoLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTJ3Lke0OlUh\|ryP	NGrVb4JUSU6JRWK=
J-RT3-T3-5	MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXX3ZZFDUUN3ME2yOk4{ODJ5IN88US=>	MYfTRW5ITVJ?
JEG-3	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7yOW1KSzVyPUK2MlY5ODVizszN	M4XGS3NCVkeHUh?=
RKO	NVzmc\|JMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2Sw[GlEPTB;Mk[uO\|Y{OiEQvF2=	MnXoV2FPT0WU
CAL-85-1	MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\rTWM2OD1{Nz6yNVE5KM7:TR?=	NHy3TFBUSU6JRWK=
CAL-120	MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTJ5Lk[5NVQh\|ryP	NITvR2xUSU6JRWK=
NCI-H2452	Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTJ5Lke3NVYh\|ryP	MkTkV2FPT0WU
NCI-H1395	M2jtS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTMelFrUUN3ME2yO{44QDN\|IN88US=>	MofNV2FPT0WU
KYSE-450	NFHOUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIG3VmRKSzVyPUK3Mlk5PjJizszN	NXe2XI1OW0GQR1XS
S-117	MoXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTJ7LkO4OVch\|ryP	Ml3JV2FPT0WU
SW13	M2jyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnu2TWM2OD1{OT64OVE6KM7:TR?=	Mlz0V2FPT0WU
ES3	NWnLUGY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTNyLkO3N\|Mh\|ryP	MlGzV2FPT0WU
HCT-116	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzFPY9vUUN3ME2zNE42PTV2IN88US=>	NFHoPFNUSU6JRWK=
NCI-H1693	MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7DTWM2OD1\|MD61PVQzKM7:TR?=	NYq4S5dRW0GQR1XS
VM-CUB-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37zemlEPTB;M{CuOlQyOyEQvF2=	MnfIV2FPT0WU
NCI-H2170	MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7wZVM4UUN3ME2zNU42Pzh2IN88US=>	MnSzV2FPT0WU
ALL-PO	MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PYSmlEPTB;M{GuPFQzQCEQvF2=	NYrQZXFvW0GQR1XS
NCI-H661	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTFTWM2OD1\|Mj6wOlI{KM7:TR?=	MUjTRW5ITVJ?
NCI-H2347	NFzKO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13Bb2lEPTB;M{KuOFg{PyEQvF2=	M33uUXNCVkeHUh?=
FTC-133	M4m4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvjTWM2OD1\|Mj63NFYh\|ryP	Mm\sV2FPT0WU
COLO-829	M1rRSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTN\|LkO0Olch\|ryP	MnLOV2FPT0WU
GOTO	NGf5XI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nKUmlEPTB;M{OuOVI2QCEQvF2=	NYXLNGVDW0GQR1XS
YAPC	NHvyN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\GPIdMUUN3ME2zN{45OTV7IN88US=>	MW\TRW5ITVJ?
LCLC-103H	NH\YdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\DOmlEPTB;M{SuNVYzPCEQvF2=	MVHTRW5ITVJ?
SiHa	MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPDWpJFUUN3ME2zOE4{QDF5IN88US=>	MUfTRW5ITVJ?
LK-2	NHnme25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrqTWM2OD1\|ND61O\|A5KM7:TR?=	NF\2W\|lUSU6JRWK=
KP-N-YS	NXzQUoJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXsV25KSzVyPUO0MlczODJizszN	M3jnfnNCVkeHUh?=
NCI-SNU-1	NFi2O3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHSSodiUUN3ME2zOU4yPzlizszN	M3z5WnNCVkeHUh?=
KNS-81-FD	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEexRoVKSzVyPUO1MlY3OyEQvF2=	NHrKNHdUSU6JRWK=
SCC-9	NGfFTnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoK4TWM2OD1\|Nj63NVQ3KM7:TR?=	M2rReHNCVkeHUh?=
SH-4	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIi5RYpKSzVyPUO2Mlc{KM7:TR?=	Mo\2V2FPT0WU
HCC-1954	MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXieYZKSzVyPUO3MlI4OjlizszN	MlyzV2FPT0WU
BALL-1	NGfxSXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfwUI1KSzVyPUO3MlU{OTZizszN	M3noNHNCVkeHUh?=
BE-13	M3[3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrkcmFKSzVyPUO3MlcxOThizszN	M{jDWHNCVkeHUh?=
COLO-678	M{PRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkT3TWM2OD1\|Nz65OFM4KM7:TR?=	M{DQNXNCVkeHUh?=
SK-MEL-3	M3fQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TG[mlEPTB;M{iuNlM6PyEQvF2=	MXjTRW5ITVJ?
OAW-28	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjyc\|hNUUN3ME2zPE43OzlizszN	MnvhV2FPT0WU
CAMA-1	NV;yflVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfaSlhKSzVyPUO4Mlk3QTFizszN	NG\kOFRUSU6JRWK=
C2BBe1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn33TWM2OD1\|OT64NVgh\|ryP	MXjTRW5ITVJ?
A3-KAW	M{j0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3S2WmlEPTB;NECuN\|Y3OSEQvF2=	NYf1endJW0GQR1XS
SK-MEL-24	NIjINIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vNNmlEPTB;NECuOVk{OSEQvF2=	MYfTRW5ITVJ?
KYSE-140	M4j0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DUTGlEPTB;NECuO\|E3PSEQvF2=	MYfTRW5ITVJ?
MOLT-16	NHPlb3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUH3R3RmUUN3ME20NU4yPTN4IN88US=>	NGW4cWxUSU6JRWK=
CFPAC-1	M3rXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHHVopIUUN3ME20Nk42OjFzIN88US=>	Mn3FV2FPT0WU
NB14	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFq4e4VKSzVyPUSyMlcxOjdizszN	NH3mS4FUSU6JRWK=
COLO-792	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXMOFhKSzVyPUSyMlg6PjFizszN	MWjTRW5ITVJ?
RH-1	M{Txd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXryfGdNUUN3ME20N{41QDN4IN88US=>	NXLKd3dYW0GQR1XS
NCI-H522	NGiwNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{i0NGlEPTB;NESuN\|U3QCEQvF2=	M3m3ZXNCVkeHUh?=
Ca-Ski	NHHMTlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHiVHJKSzVyPUS0MlgyOTRizszN	M3u2UnNCVkeHUh?=
KGN	MnvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fZfmlEPTB;NEiuN\|A3OyEQvF2=	MWrTRW5ITVJ?
UACC-62	M2Hmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILDWZpKSzVyPUS4MlQxPzJizszN	NG\BTIZUSU6JRWK=
NCI-H358	NXTtWXVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTR7LkOwNVgh\|ryP	NV3uXolrW0GQR1XS
LS-411N	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHRZnlZUUN3ME20PU4{OTF6IN88US=>	M3L4TXNCVkeHUh?=
IST-MES1	NVP1SVh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTR7LkW2NlUh\|ryP	NXG2ZmhFW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT / AKT / p-FoxO3a / FoxO3a / PUMA; PubMed: 29137323 Oncotarget HCT116 cells were treated with 4μmol/L NVP-BKM120 or 4μmol/L Pictilisib for 24 hours. Indicated protein levels were analyzed by Western blotting. p-S6RP / S6RP; PubMed: 30042442 Cell Death Dis Western blot analysis of proteins as indicated in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. Vinculin was used as a loading control. p-4EBP1 / 4EBP1; PubMed: 25857298 Oncotarget Cells were treated with 0.5 μM GDC-0941 for the indicated time course and then collected for Western blot analysis of p-4EBP1. p-LRP6 / LRP6; PubMed: 25857298 Oncotarget MDAMB-231, HCC1937 and MCF7 cells were treated with 0.5 µM GDC-0941 for 1 hr, and cell lysates were used for immunoblot analyses. p-PAK / PAK1 / p-CRAF / RAF / p-MEK / MEK / p-ERK / ERK; PubMed: 24327733 Proc Natl Acad Sci U S A Cells were treated with 1 μM GDC-0941 for the indicated times, and lysates were probed with the indicated antibodies. Independent experiments were performed at least three times, and a representative result is shown.	29137323 30042442 25857298 24327733
Immunofluorescence	p65; PubMed: 30042442 Cell Death Dis Representative images of immunofluorescent staining of p65 cellular localization in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. 4T1 cells were cultured alone or co-cultured with RAW264.7 macrophages. Representative images of three independent experiments are shown. beta-catenin; PubMed: 25857298 Oncotarget Cells were seeded on coverslips the day before the experiment and treated with 0.5 µM GDC-0941 for 18 hr. The immunofluorescence (IF) of beta-catenin is indicated as red fluorescence, and double staining with DAPI is blue. Magnification: 400 X for the left three panels. The right panel shows enlarged images from the white squares.	30042442 25857298
Growth inhibition assay	Cell viability; PubMed: 27117832 J Thorac Oncol The viability of the indicated cells treated with increasing concentrations of GDC-0941 (ranging from 70nM to 20 μM) for 72 hours, determined by CellTiter Glo Viability assay. The IC50 concentrations were calculated using GraphPad Prism program. The assay was performed in triplicate, and the error bars represent standard deviations.	27117832

体内研究

在微粒体中，GDC-0941仅有有限的代谢，其口服生物利用度为78%^[5]。GDC-0941 每天按 75 mg/kg剂量处理携带人U87MG 恶性胶质移植瘤的雌性NCr无胸腺小鼠，显著抑制生长，肿瘤生长抑制率为 83%。^[1]GDC-0941 每天按 150 mg/kg剂量口服处理携带HER2扩增的抗Trastuzumab的MDA-MB-361.1移植瘤的小鼠，抑制肿瘤生长，且显著延迟肿瘤衰退，与肿瘤中强诱导型凋亡相关。^[2] GDC-0941 每天按75 mg/kg剂量处理携带自发性B细胞滤泡性淋巴瘤的PTEN^+/-LKB1^+/hypo小鼠，持续2周，诱导肿瘤体积下降~40%，伴随着AKT, S6K 和SGK(血清和糖皮质激素蛋白激酶)蛋白激酶的磷酸化被切除。GDC-0941抑制肿瘤细胞增殖，诱导凋亡和抑制中心母细胞数。^[3]

激酶实验： ^[1]	- 合并闪烁接近检测: 使用p85α调节亚基，使重组人PI3Kα, PI3Kβ, 和PI3Kδ在 Sf9 杆状病毒系统中共表达，在谷胱甘肽-琼脂糖凝胶上进行亲和层析而纯化GST-融合蛋白。重组人 PI3Kγ表达作为单体 GST融合，也想上述相似方法纯化。GDC-0941 溶于DMSO，加到含200 μg硅酸钇(Ysi) 聚赖氨酸SPA 磁珠, 4 mM MgCl₂, 1 mM 二硫苏糖醇 (DTT), 1 μM ATP, 0.125 μCi [γ-³³P]-ATP, 和4% (v/v) DMSO的20 mM Tris-HCl (pH 7.5)上，总体积为 50 μL。PI3Kα (5 ng), PI3Kβ(5 ng), PI3Kδ(5 ng), 或PI3Kγ(5 ng)的重组GST-融合，加到实验混合物中，开始激酶反应。在室温下温育1小时后, 加入150 μL PBS终止反应。混合物在2000 rpm 转速下离心2分钟，然后使用Wallac Microbeta计数器读数。在 MDL Assay Explorer系统中使用S型，剂量-反应曲线，计算进行至少2次独立重复实验，取平均值，作为IC50值。
细胞实验： ^[2]	- 合并 Cell lines: SKBR-3, BT474-M1, AU-565, HCC-1419, ZR75-30, KPL-4, JIMT-1, BT474-EEI, HCC-1954, MCF-7, CALU-3, SKOV-3, 和MKN-7 Concentrations: 溶于DMSO,终浓度为~10 μM Incubation Time: 48,和72小时 Method: 使用不同浓度 GDC-0941处理细胞48,和 72小时。通过CellTiter-Glo Luminescent细胞活性检测实验测定细胞增殖/活力。通过Western Blot分析pAKT (Ser473), cleaved caspase-3, 和cleaved PARP通过 Caspase-Glo 3/7实验和细胞死亡检测 ELISAplus 实验分别测定caspase 3/7活性, 和凋亡。 (Only for Reference)
动物实验： ^[2]	- 合并 Animal Models: 移植MDA-MB-361.1细胞的NCR裸鼠, 皮下移植BT474-M1 细胞的SCID, C.B-17/IcrHsd-Prkdc^scid 小鼠 Formulation: 溶于10% DMSO, 5% Tween-20, 85% 水 Dosages: ~150 mg/kg/day Administration: 口服饲喂 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	44 mg/mL (85.66 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+30% PEG 300+5% Tween 80+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Pictilisib (GDC-0941) SDF

分子量	513.64
化学式	C₂₃H₂₇N₇O₃S₂
CAS号	957054-30-7
储存条件	3年 -20°C粉状
储存条件	2年 -80°C 溶于溶剂
别名	RG7321

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02092831	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	April 2014	Phase 1
NCT01740336	Completed	Drug: GDC-0941\|Drug: Placebo\|Drug: Paclitaxel	Breast Cancer	Genentech Inc.	February 6 2013	Phase 2
NCT01474668	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	October 2011	Phase 1
NCT01240226	Completed	Drug: GDC-0941\|Drug: ketoconazole	Healthy Volunteer	Genentech Inc.	November 2010	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

泛PI3K抑制剂

LY294002 : Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.
活性最高的PI3K抑制剂

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA批准的PI3K抑制剂

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
最新的PI3K抑制剂

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

研究领域

产品类型

Pictilisib (GDC-0941)

客户使用Selleck生产的Pictilisib (GDC-0941)发表文献294篇：

产品安全说明书

PI3K抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Pictilisib (GDC-0941) SDF

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

技术支持

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品